Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction

Journal article

S Boyle, C Wellard, EM Moore, H Blacklock, SJ Harrison, PJ Ho, J Hocking, ZK McQuilten, H Quach, R Spearing, EM Wood, A Spencer, P Mollee

European Journal of Haematology | WILEY | Published : 2021